Targeting angiogenic processes by combination rofecoxib and ionizing radiation.

Area of Science:

• Molecular Biology
• Oncology
• Pharmacology

Background:

• Tumor growth and angiogenesis are closely linked processes.
• Cyclooxygenase-2 (COX-2) plays a significant role in inflammation and cancer development.
• COX-2 inhibitors like rofecoxib show efficacy in pain and inflammation management with reduced gastrointestinal risks.

Purpose of the Study:

• To investigate the effects of rofecoxib, alone and in combination with radiation, on cytokine-induced angiogenesis in vitro.
• To evaluate the potential of combining rofecoxib and radiation as an anti-angiogenic cancer therapy.

Main Methods:

• In vitro assessment of cytokine-induced angiogenesis.
• Evaluation of rofecoxib at various concentrations on endothelial cell proliferation, migration, and tube formation.
• Assessment of the combined effect of rofecoxib and radiation on endothelial cell function.

Main Results:

• Rofecoxib demonstrated dose-dependent inhibition of endothelial cell proliferation, migration, and tube formation at clinically relevant concentrations.
• The combination of rofecoxib and radiation resulted in a twofold increase in the inhibition of endothelial cell function compared to rofecoxib alone.
• These findings suggest a synergistic anti-angiogenic effect when rofecoxib and radiation are used together.

Conclusions:

• Rofecoxib effectively inhibits key endothelial cell functions involved in angiogenesis.
• The combination of rofecoxib and radiation presents a promising complementary strategy for targeting angiogenesis in malignancies.
• This approach warrants further investigation for clinical applications in cancer treatment.